Forum Discussion
A 62-year-old retired civil servant presents to the clinic reporting right upper quadrant abdominal pain and progressive early satiety. He also notes an unintentional 6 kg weight loss over the past three months. Physical examination reveals mild conjunctival icterus alongside firm, non-tender hepatomegaly extending 4 cm below the right costal margin. His ECOG performance status is 1.
Abdominal contrast-enhanced CT demonstrates a hypervascular 7.5 cm mass in the right hepatic lobe with peripheral rim enhancement. Two smaller satellite nodules are visible nearby. The multidisciplinary tumor board deems the lesion unresectable. Core needle biopsy confirms moderately differentiated intrahepatic cholangiocarcinoma.
Baseline laboratory parameters show a total bilirubin of 1.8 mg/dL. Hepatic transaminases are elevated, with an AST of 64 U/L and an ALT of 58 U/L. Serum CA 19-9 is elevated at 480 U/mL. Next-generation sequencing confirms microsatellite stability, identifying no actionable FGFR2 fusions or IDH1 mutations. The patient and his family will finance all oncology care strictly out of pocket, a common reality in our local clinical setting.
Discussion Questions
-
How does the protocol mandate to stop gemcitabine at cycle 8 in TOPAZ-1 compare structurally with the continuous maintenance allowed in KEYNOTE-966? What do the respective survival curves tell us about these different approaches?
-
Balancing clinical efficacy with the high risk of financial toxicity in Nigeria, how do you navigate the conversation with this self-funding family when deciding between fixed-duration durvalumab and potentially indefinite pembrolizumab?
-
If out-of-pocket funds become exhausted during maintenance immunotherapy, what practical dose-modification strategies or altered surveillance protocols could you implement to maximize the patient's existing tumor response?